-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Light stimulants are commonly used in the production of various common products, including adhesives, items in the printing industry (inks, printing plates), toys (manufacturing of 3D objects), and materials in the medical field (dental filling materials and artificial tissues), etc.
Many of them can produce toxic reactions to the human body under certain conditions, and even have certain estrogenic activity
.
The breast development is closely related to exposure to estrogen hormone
1.
The effect of tamoxifen on tumor growth in xenotransplanted mice
In addition, there was no significant difference in weight change between the groups (Figure 3D)
Tamoxifen (0.
In summary, this study confirmed that the three light stimulants 1-HCHPK, MBB and MTMP have estrogenic activity and can promote the development of breast cancer
.
And estrogen receptor antagonists, such as tamoxifen, can inhibit the effect of light stimulants on breast cancer
Light stimulants are commonly used in the production of various common products, including adhesives, items in the printing industry (inks, printing plates), toys (manufacturing of 3D objects), and materials in the medical field (dental filling materials and artificial tissues), etc.
This study used MCF-7 breast cancer cell transplantation mouse models to detect the estrogenic activity of 1-HCHPK, MBB, and MTMP to confirm the endocrine disrupting effect of light stimulants
In addition, there was no significant difference in weight change between the groups (Figure 3D)
There was no significant difference between the 0.
3.
In 1-HCHPK-treated mice, pretreatment with the ER antagonist tamoxifen reversed the increase in tumor volume induced by 1-HCHPK (Figure 4A)
Leave a message here
Many of them can produce toxic reactions to the human body under certain conditions, and even have certain estrogenic activity
.
The breast development is closely related to exposure to estrogen hormone
1.
In general, mice injected with light stimulants 1-HCHPK, MBB, and MTMP showed a significant increase in tumor volume, indicating that these three photoinitiators promoted the development of breast cancer in mice
.
The effect of tamoxifen on tumor growth in xenotransplanted mice
There was no significant difference between the 0.
5, 5, and 50 mg/kg groups and the control group ( Figure 2d)
.
In addition, there was no significant difference in weight change between the groups (Figure 3D)
3.
The effect of ER antagonist on the effect of light stimulants in tumor transplanted mice
In 1-HCHPK-treated mice, pretreatment with the ER antagonist tamoxifen reversed the increase in tumor volume induced by 1-HCHPK (Figure 4A)
.
Tamoxifen (0.
In summary, this study confirmed that the three light stimulants 1-HCHPK, MBB and MTMP have estrogenic activity and can promote the development of breast cancer
.
And estrogen receptor antagonists, such as tamoxifen, can inhibit the effect of light stimulants on breast cancer
Light stimulants are commonly used in the production of various common products, including adhesives, items in the printing industry (inks, printing plates), toys (manufacturing of 3D objects), and materials in the medical field (dental filling materials and artificial tissues), etc.
This study used MCF-7 breast cancer cell transplantation mouse models to detect the estrogenic activity of 1-HCHPK, MBB, and MTMP to confirm the endocrine disrupting effect of light stimulants
In general, mice injected with light stimulants 1-HCHPK, MBB, and MTMP showed a significant increase in tumor volume, indicating that these three photoinitiators promoted the development of breast cancer in mice
.
There was no significant difference between the 0.
5, 5, and 50 mg/kg groups and the control group ( Figure 2d)
.
In addition, there was no significant difference in weight change between the groups (Figure 3D)
There was no significant difference between the 0.
3.
In 1-HCHPK-treated mice, pretreatment with the ER antagonist tamoxifen reversed the increase in tumor volume induced by 1-HCHPK (Figure 4A)
Leave a message here
